Nowa wersja platformy, zawierająca wyłącznie zasoby pełnotekstowe, jest już dostępna.
Przejdź na


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2010 | 5 | 2 | 261-267
Tytuł artykułu

Association of osteoprotegerin and rankl levels with insulin resistance in pubertal obese children

Treść / Zawartość
Warianty tytułu
Języki publikacji
Osteoprotegerin (OPG)/“receptor activator of nuclear factor kappa B-ligand” (RANKL) system has an important role in the remodeling of bone through regulation of osteoclastogenesis. We aimed to detect OPG and RANKL levels, particularly in obese children in the pubertal period and to investigate whether these parameters correlate with insulin resistance in childhood. Our study included 66 obese children ranging in age from 9.1 to 16 years, and 22 non-obese children ranging in age from 10.5 to 16 years. Blood glucose, insulin, total cholesterol, HDL cholesterol, and LDL cholesterol levels were measured for all cases; HOMA-IR, Quicki index and atherogenic index were calculated. Serum OPG and RANKL levels were also measured. OPG and RANKL levels did not show any difference between obese and non-obese children (P>.05). No difference in these 2 parameters were observed among the children with and without insulin resistance (P>.05). No correlation could be established between the OPG, the HOMA-IR, Quick and atherogenic indices. Obesity and insulin resistance are believed to show their effect in the later period of life to become able to change some of the parameters.

Opis fizyczny
  • Department of Pediatric Endocrinology, Gazi University Medical School, 06200, Ankara, Turkey,
  • Department of Pediatric Endocrinology, Gazi University Medical School, 06200, Ankara, Turkey
  • Department of Pediatric Endocrinology, Gazi University Medical School, 06200, Ankara, Turkey
  • Department of Pediatric Endocrinology, Gazi University Medical School, 06200, Ankara, Turkey
  • Department of Pediatric Neurology, Gülhane Military Medical Academy, 06018, Ankara, Turkey
  • Department of Pediatric Endocrinology, Gazi University Medical School, 06200, Ankara, Turkey
  • [1] Alemzadeh R., Rising R., Lifshitz F., Obesity in Children, In: Lifshitz F., Editor. Pediatric Endocrinology. New York: Healthcare, 2007, 1–36
  • [2] Güngör N., Arslanian S.A., Nutritional disorders, In: Sperling M.A., Editor. Pediatric Endocrinology. Philadelphia: Saunders, 2002, 689–724
  • [3] Hasanoğlu A., Bideci A., Cinaz P., Tümer L., Unal S, Bone mineral density in childhood obesity., J. Pediatr. Endocrinol. Metab., 2000, 13, 307–311
  • [4] Rocher E., Chappard C., Jaffre C., Benhamou CL., Courteix D., Bone mineral density in prepubertal obese and control children: relation to body weight, lean mass, and fat mass., J. Bone. Miner. Metab., 2008, 26, 73–78[WoS][Crossref]
  • [5] Schoppet M., Preissner K.T., Hofbauer L.C., RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function., Arterioscler. Thromb. Vasc. Biol., 2002, 22, 549–553[Crossref]
  • [6] Browner W.S., Lui L.Y., Cummings S.R., Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women., J. Clin. Endocrinol. Metab., 2001, 86, 631–637[Crossref]
  • [7] Indridason O.S., Franzson L., Sigurdsson G., Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover., Osteoporos. Int., 2005, 16, 417–423[Crossref]
  • [8] Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., et al, Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification., Genes. Dev., 1998, 12, 1260–1268[Crossref]
  • [9] Rogers A., Saleh G., Hannon R.A., Greenfield D., Eastell R., Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women., J. Clin. Endocrinol. Metab., 2002, 87, 4470–4475[Crossref]
  • [10] Rouster-Stevens KA, Langman CB, Price HE, Seshadri R, Shore RM, Abbott K, et al. RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis. Arthritis Rheum 2007; 56: 977–983[Crossref][WoS]
  • [11] Franck H., Meurer T., Hofbauer L.C., Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis., J. Rheumatol., 2004, 31, 2236–2241
  • [12] Min H., Morony S., Sarosi I., Dunstan C.R., Capparelli C., Scully S., et al., Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis., J. Exp. Med., 2000, 192, 463–474[Crossref]
  • [13] Anand D.V., Lahiri A., Lim E., Hopkins D., Corder R., The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects., J. Am. Coll. Cardiol., 2006, 47, 1850–1857
  • [14] Bundak R., Furman A., Gunoz H., Darendeliler F., Bas F., Neyzi O., Body mass index references for Turkish children., Acta. Paediatr., 2006, 95, 194–198[Crossref]
  • [15] Keskin M., Kurtoglu S., Kendirci M., Atabek M.E., Yazici C., Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents., Pediatrics, 2005, 115, e500–503[Crossref]
  • [16] Buzi F., Maccarinelli G., Guaragni B., Ruggeri F., Radetti G., Meini A., et al., Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner’s syndrome and rheumatoid arthritis., Clin. Endocrinol. (Oxf)., 2004, 60, 87–91[Crossref]
  • [17] Misra M., Soyka L.A., Miller K.K., Herzog D.B., Grinspoon S., De Chen D., et al., Serum osteoprotegerin in adolescent girls with anorexia nervosa., J. Clin. Endocrinol. Metab., 2003, 88, 3816–3822[Crossref]
  • [18] Ugur-Altun B., Altun A., Circulating leptin and osteoprotegerin levels affect insulin resistance in healthy premenopausal obese women., Arch. Med. Res., 2007, 38, 891–896[Crossref][WoS]
  • [19] Oh E.S., Rhee E.J., Oh K.W., Lee W.Y., Baek K.H., Yoon K.H., et al., Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women., Metabolism, 2005, 54, 49–54[Crossref]
  • [20] Gannagé-Yared M.H., Yaghi C., Habre B., Khalife S., Noun R., Germanos-Haddad M., et al., Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study., Eur. J. Endocrinol., 2008, 158, 353–359[Crossref][WoS]
  • [21] Szulc P., Hofbauer L.C., Heufelder A.E., Roth S., Delmas P.D., Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status., J. Clin. Endocrinol. Metab., 2001, 86, 3162–3165[Crossref]
  • [22] Swolin-Eide D., Magnusson P., Hansson S., Bone mass, biochemical markers and growth in children with chronic kidney disease: a 1-year prospective study., Acta Paediatr., 2007, 96, 720–725[WoS][Crossref]
  • [23] Angelopoulos N.G., Goula A., Katounda E., Rombopoulos G., Kaltzidou V., Kaltsas D., et al., Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in patients with betathalassemia major., J. Bone. Miner. Metab., 2007, 25, 60–67[Crossref]
  • [24] Ugur-Altun B., Altun A., Gerenli M., Tugrul A., The relationship between insulin resistances assessed by HOMA-IR and serum osteoprotegerin levels in obesity., Diabetes Res. Clin. Pract., 2005, 68, 217–222[Crossref]
  • [25] Gannagé-Yared M.H., Fares F., Semaan M., Khalife S., Jambart S., Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population., Clin. Endocrinol. (Oxf)., 2006, 64, 652–658[Crossref]
  • [26] Altun A., Ugur-Altun B., Tatli E., Decreased serum osteoprotegerin levels in patients with cardiac syndrome X., J. Endocrinol. Invest., 2004, 27, 839–843 [Crossref]
  • [27] Kim S.M., Lee J., Ryu O.H., Lee K.W., Kim H.Y., Seo J.A., et al., Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity., Clin. Endocrinol. (Oxf)., 2005, 63, 594–598[Crossref]
  • [28] Uemura H., Yasui T., Miyatani Y., Yamada M., Hiyoshi M., Arisawa K., et al., Circulating osteoprotegerin is associated with age and systolic blood pressure, but not with lipid profile or fasting glucose, in postmenopausal women., Menopause, 2008, 15, 180–184 [WoS]
  • [29] Dovio A., Allasino B., Palmas E., Ventura M., Pia A., Saba L., et al., Increased osteoprotegerin levels in Cushing’s syndrome are associated with an adverse cardiovascular risk profile., J. Clin. Endocrinol. Metab., 2007, 92, 1803–1808[Crossref]
  • [30] Rhee E.J., Oh K.W., Jung C.H., Lee W.Y., Oh E.S., Yun E.J., et al., The relationship between four single nucleotide polymorphisms in the promoter region of the osteoprotegerin gene and aortic calcification or coronary artery disease in Koreans., Clin. Endocrinol. (Oxf)., 2006, 64, 689–697[Crossref]
Typ dokumentu
Identyfikator YADDA
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.